Animal Study Confirms Caprospinol's (SP-233) Ability to Clear Brain Plaque and Empower Rat Brain Cells to Recover Memory Function
In Vivo 'Proof of Concept' Study Proposes Direct Correlation Between Removing Beta Amyloid Plaque and Memory Recovery
LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce it has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in-vitro data and suggests Caprospinol may not only slow down Alzheimer's but may also reverse plaque-related brain injuries associated with the mind-robbing disease of Alzheimer's.
The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills. Plaque can cause swelling and bumps on nerve cells, making it hard or even impossible for the cells to communicate. While the cause of Alzheimer's disease still remains unknown, a growing number of researchers are indicating that plaque formation and accumulation may play a role.
The study was conducted by Samaritan's collaborating researchers, including Dr. Laurent Lecanu and Dr. Vassilios Papadopoulos.
Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "Memory recovery in rats is a lot simpler than curing Alzheimer's disease in people but these study results are extremely encouraging. The rats tested with our proprietary Alzheimer's rat model took on features similar to the crippling dementia seen in a human's Alzheimer's brain, and then, by treating the rats with Caprospinol, the rat's brain cells bounced back with complete memory."
Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."
Samaritan Pharmaceuticals is a life science company focused on commercializing innovative drugs to relieve the suffering of patients with Alzheimer's, Cancer, Heart disease, and Infectious disease. Samaritan's business strategy is to partner its later stage drugs after Phase II (proof of concept) human studies and has executed its first partnership for its PII, HIV drug SP-01A, with Pharmaplaz, Ireland. Samaritan's Alzheimer's drug Caprospinol has received investigational new drug (IND) status from the FDA and Samaritan has several other drugs it is advancing to enter (IND) status. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in various Eastern European countries.
Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business , please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
-0- CONTACT: Samaritan Pharmaceuticals, Inc. Richard Brown (702) 735-7001 RichardBrown@SamaritanPharma.com